Screening and classifying small-molecule inhibitors of amyloid formation using ion mobility spectrometry-mass spectrometry by Young, LM et al.
	



	
		
	
		
	

	
				
 !

∀
#∃%∃&∃∋(∃%

∃)∃∃(∗∃+
	∃∋∃∃,∗∃#∃−.∃

∃&/)
	∃)/0 123&#4#5,5
6	


54

5	
#
5
6	4	
5	4,5	
5	47	
(5	4∃!023!8,29&&72!,:881
		;

#212187(∗/% 2 <
	
		
	=	

				

Screening and classifying small molecule inhibitors of amyloid formation using ion 
mobility spectrometry-mass spectrometry 
 
Lydia M. Young1,2#, Janet C. Saunders1,2#, Rachel A. Mahood1,2, Charlotte H. Revill1,3, 
Richard J. Foster1,3, Ling-Hsien Tu4, Daniel P. Raleigh4, Sheena E. Radford1,2*, Alison 
E. Ashcroft1,2* 
 
 
 
1. Astbury Centre for Structural Molecular Biology, University of Leeds, LS2 9JT, UK;  
2. School of Molecular and Cellular Biology, University of Leeds, LS2 9JT, UK;  
3. School of Chemistry, University of Leeds, LS2 9JT, UK;  
4. Department of Chemistry, Stony Brook University, Stony Brook, NY 11794-3400, 
USA. 
 
 
# These authors contributed equally to this work. 
 
 
 
* Corresponding authors: 
email: s.e.radford@leeds.ac.uk and a.e.ashcroft@leeds.ac.uk 
 
  
1 
 
Abstract 
The search for therapeutic agents which bind specifically to precursor protein conformations 
and inhibit amyloid assembly is an important challenge. Identifying such inhibitors is difficult 
since many protein precursors of aggregation are partially folded or intrinsically disordered, 
ruling out structure-based design. Furthermore, inhibitors can act by a variety of 
mechanisms, including specific or non-specific binding, as well as colloidal inhibition. Here 
we report a high throughput method based on ion mobility spectrometry-mass spectrometry 
(IMS-MS) that is capable of rapidly detecting small molecules that bind to amyloid 
precursors, identifying the interacting protein species, and defining the mode of inhibition. 
Using this method we have classified a variety of small molecules that are potential inhibitors 
of human islet amyloid polypeptide (hIAPP) aggregation or amyloid-beta 1-$ȕ
aggregation as either specific, non-specific, colloidal or non-interacting. We also 
demonstrate the ability of IMS-MS to screen for inhibitory small molecules in a 96-well plate 
format and use this to discover a new inhibitor of hIAPP amyloid assembly. 
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Main Text 
Aberrant aggregation of proteins and peptides into amyloid fibrils contributes to more than 50 
human disorders, including Alzheimer's disease and type-2 diabetes mellitus1. The ability to 
screen for compounds able to disrupt protein aggregation, and assess their mode of action, 
is instrumental in therapy discovery. For folded proteins, structure-based design has been 
used to create small molecules able to stabilize the native state, thereby preventing the 
conformational changes required for protein aggregation to occur2-4. For aggregation-prone 
proteins that lack defined structure, discovery of small molecule inhibitors of aggregation is 
limited to screening using relatively low resolution approaches such as dye binding assays. 
Most biophysical techniques lack the sensitivity and resolution to detect and individually 
characterize oligomers during aggregation and, therefore, are not suitable for characterizing 
unique protein subspecies with which the small molecule inhibitor interacts5. Dye binding 
assays can also be compromised by competitive binding of the small molecule to the dye-
binding site on the protein and by inner filter effects which can interfere with the fluorescence 
of the dye6-8. 
 
Electrospray ionization-ion mobility spectrometry-mass spectrometry (ESI-IMS-MS) 
circumvents the disadvantages of other in vitro screening techniques, allowing the rapid 
identification of inhibitors, the characterization of their mechanism of action, and the 
identification of the individual species to which the small molecule binds9-11. Here, we 
demonstrate the capability of ESI-IMS-MS to screen for, and analyze, the mode of 
interaction of a range of small molecules with human islet amyloid polypeptide (hIAPP, also 
known as amylin), a peptide associated with ȕ-cell death in type-2 diabetes mellitus12 and 
the failure of islet transplants, and amyloid beta 1-$ȕ40)13, a peptide associated with 
Alzheimer’s disease. ESI-IMS-MS has a number of additional benefits: it is rapid (<1 
minute/sample), consumes low amounts of sample (~1000 molecules screened/mg protein), 
does not require sample labeling or immobilization, and provides stoichiometric and 
conformer-specific information. Additionally, colloidal inhibitors (that self-aggregate and 
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physically sequester proteins non-specifically14), that may erroneously be classified as “hits” 
in other assays, are immediately identifiable. While several small molecules have been 
shown to inhibit the fibrillation of K,$33DQGRU$ȕ in vitro10,15-20, their mechanisms of 
action remain poorly understood. Using a selection of small molecules (Supplementary, 
Section 1 and Table S1), we demonstrate the ability of ESI-IMS-MS to differentiate and 
classify compounds that do not bind, and those that bind specifically, non-specifically or 
colloidally, to hIAPP and $ȕ (Figure 1). Furthermore, we use the method developed to 
screen a further thirty compounds to demonstrate that it can be implemented in a high 
throughput mode and, in doing so, reveal a new specific inhibitor of hIAPP aggregation. 
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Results and Discussion 
hIAPP forms oligomeric assemblies and fibrils in absence of inhibitor 
The ESI mass spectrum of hIAPP (Figure 2a) shows predominantly monomer-related ions 
(e.g. 12+ and 13+) together with traces of dimer and trimer (Figure 2b). hIAPP aggregates 
during fibril assembly forming oligomers dimer through to hexamer early in assembly which 
are readily observed using ESI-IMS-MS10 (Figure 2c). The higher order oligomers appear 
and subsequently disappear as aggregation proceeds, resulting in the formation of long 
straight amyloid fibrils10 (Figure 2b, inset). 
 
ESI-IMS-MS-based screening approach 
To determine the mode of action of different small molecules in inhibiting hIAPP self-
assembly, 10 compounds were evaluated initially (Figure 1e). These were chosen because 
they, or their analogues, have been shown previously to inhibit, or have no observed effect, 
on amyloid formation (Supplementary, Section 1). Molar ratios of small molecule:hIAPP of 
1:1 and 10:1 were used. The monomer and oligomer populations in the presence of each 
small molecule were characterized using ESI-IMS-MS. This technique has been 
implemented successfully to determine and rank ligand binding affinities22-24. However, ESI-
MS can suffer from the drawback that hydrophobic interactions are not wholly maintained in 
the gas-phase which can lead to underestimates of binding affinity and/or false negative 
results. For this reason, fibril formation was also monitored using thioflavin T (ThT) 
fluorescence and the morphologies of the resulting aggregates were assessed using 
negative stain transmission electron microscopy (TEM). The objectives were to (i) observe 
interactions between peptide monomers or oligomers and each small molecule; (ii) 
determine how these interactions affect the distribution of monomeric conformers and 
oligomers; and (iii) elucidate whether any changes observed can be correlated with the 
inhibition (or lack of inhibition) of hIAPP amyloid formation.  
 
Mode of action of a positive inhibitor of hIAPP fibril assembly 
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Using the ESI-IMS-MS-based screening approach described, the 10 compounds selected 
based on their known effect on hIAPP aggregation (Supplementary, Section 1 & Table S1) 
were analyzed. One of these was Fast Green FCF (1) (FG), a known inhibitor of hIAPP fibril 
formation25.  
 
Consistent with previous reports25, ThT fluorescence and TEM (Figure 3a,b) confirmed that 
FG inhibits amyloid formation by hIAPP in vitro. However, the mechanism by which it inhibits 
assembly was unknown. Here, using ESI-IMS-MS, FG was found to bind to the 2+ and 3+ 
monomeric charge states of hIAPP (Figure 3c). Our previous work10, and that of others26, 
has shown that each hIAPP monomeric charge state (2+ and 3+) populates at least two 
conformers (extended and compact, with the more expanded structure proposed to be 
amyloid-prone). Analysis of the ESI-IMS-MS data reveals that FG alters the distribution of 
charge states and the monomeric conformers present, increasing the relative abundance of 
the 3+ monomer ion (Figure 3c) and the proportion of compact conformers compared with 
those observed for hIAPP alone (Supplementary, Figure S1). The interaction of FG likely 
involves the sulfonated groups forming favorable electrostatic interactions with positively 
charged hIAPP at pH 6.8 (hIAPP pI ؄ 8.9). Consistent with this, the extent of binding is 
dependent on the buffer ionic strength (Supplementary, Figure S2). Factors other than 
electrostatic complementarity must contribute to the specific binding of FG, however, as not 
all sulfonated small molecules are inhibitors of hIAPP amyloid assembly (Supplementary, 
Section 1 & Figure S3). For two other known positive inhibitors, EGCG (epigallocatechin 
gallate)10,16 (2) and silibinin10,27 (3), low levels of binding are observed, despite complete 
inhibition of fibrillation, indicative of hydrophobic interactions playing a role in the binding 
interface. Unlike the hIAPP-FG interaction, this mode of binding is relatively insensitive to 
buffer ionic strength (Supplementary, Figure S2).      
 
Colloidal inhibition characterized using ESI-IMS-MS 
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Congo red (CR) (4), was analysed as an example of a known colloidal inhibitor of hIAPP 
assembly28. At a 1:1 molar ratio of hIAPP:CR, a small increase in the rate of fibril formation 
was observed, with no significant change in the hIAPP mass spectrum (Figure 4a-c). 
However, at a 10:1 molar ratio of CR:hIAPP, no fibrillation was observed (Figure 4a,b). 
These data are consistent with previous reports that CR promotes fibril formation in some 
systems at low concentrations29 but inhibits protein self-assembly when present at high 
concentrations (100-200 µM)14. Using ESI-IMS-MS, CR alone is observed to self-associate 
at high concentrations (320 µM), with aggregates ranging in size from ~5-11 copies 
(Supplementary, Figure S4). No binding of CR monomer to monomeric hIAPP was observed 
(Figure 4c), consistent with colloidal inhibition resulting from supramolecular assemblies of 
CR inhibiting fibril formation at high ligand concentrations. 
 
Non-specific binding and lack of inhibition characterized using ESI-IMS-MS 
Although not reported as an inhibitor of hIAPP aggregation, 1H-benzimidazole-2-sulfonic 
acid (1H-B-SA) (5) possesses both aromatic and anionic moieties known to be important for 
the interaction of small molecules with amyloid proteins and peptides30.  
The mass spectrum of a 10:1 molar ratio of 1H-B-SA and hIAPP is indicative of non-specific 
binding, resulting in a series of ions with multiple ligands bound, following a Poisson 
distribution21,22 (Figure 4c). As an interaction of this type often involves charge, it is less 
sensitive to structure and can be maintained during the ESI process22. Additionally, these 
types of interactions can be more stable in the gas-phase than hydrophobic interactions24, 
such as proposed for hIAPP and EGCG (2)10. Consistent with this, the ion intensity of the 
1H-B-SA:hIAPP complex is decreased at increased ionic strength (Supplementary, Figure 
S2). Non-specific interactions can be distinguished from specific interactions (that show a 
binomial distribution21) by comparison of the binding profiles (Figure 1). To confirm 
annotation as a non-specific binding ligand, a second analysis performed at lower 
ligand:peptide ratio may be required to avoid ambiguity that may arise by specific binding of 
molecules forming multiply bound complexes at high ligand:peptide ratios.  
7 
 
 ThT fluorescence and TEM investigation indicated that non-specific binding of 1H-B-SA  to 
hIAPP does not inhibit fibril formation (Figure 4a,b). Similarly, the mass spectrum of a 10:1 
molar ratio of tramiprosate (3-amino-1-propanesulfonic acid) (6) and hIAPP is also indicative 
of a non-inhibitory, non-specific interaction, which is confirmed by TEM (Supplementary, 
Figure S3). Importantly, for the compounds aspirin (7), ibuprofen (8), benzimidazole (9) and 
hemin (10) (Supplementary, Section 1 & Table S1), no evidence for binding to monomeric 
hIAPP, alteration in the monomer charge state distribution, or oligomer population, was 
observed using ESI-IMS-MS and fibrils were observed to form as shown by TEM 
(Supplementary, Figure S5). Previous studies using CD spectroscopy and Congo red 
binding assays led to the erroneous conclusion that aspirin is an inhibitor of hIAPP amyloid 
formation31, illustrating how ESI-IMS-MS helps avoid false positive results. 
 
Predicting the inhibitory potential of small molecules against amyloid formation from their 
structure alone is difficult, since structural analogues can show significant variability in 
aggregation inhibition5LIDP\FLQ69IRUH[DPSOHFDQEORFNILEULOIRUPDWLRQE\ȕ2-
PLFURJOREXOLQȕ2m), while other rifamycins are ineffective32. Similarly, derviatives of EGCG 
have marked differences in their inhibitory capacity33. The LogP value (the log of the 
hydrophobic partition coefficient) of each small molecule tested was calculated to determine 
the diversity in hydrophobicity of the compounds tested and to deduce any correlation with 
their ability to inhibit amyloid formation (Supplementary, Figure S6). The LogP values of the 
positive inhibitors range from -4.4 (FG) to +2.2 (EGCG), suggesting that polarity is not the 
only important factor for binding. Both hydrophilic FG and hydrophobic EGCG inhibit hIAPP 
aggregation, confirming that the MS-based method for screening inhibitors is capable of 
observing both electrostatic and hydrophobic interactions between amyloidogenic peptides 
and aggregation inhibitors. 
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Further analyses using Collision Induced Dissociation (CID) MS/MS showed that the specific 
inhibitors bind more tightly than their non-specific counterparts, as judged by their gas-phase 
stability (Supplementary, Figure S7), providing an additional means of selecting ligands for 
further analysis. Arrival time distribution (ATD) plots from ESI-IMS-MS experiments also 
provide evidence for the type of interaction occurring. With FG bound, there is a shift in the 
ATD plot towards more compact hIAPP monomeric protein species (Supplementary, Figure 
S8).  
 
Oligomer formation in the presence of small molecule inhibitors 
ESI-IMS-MS was utilized to determine the individual nature and abundance of the lowly-
populated hIAPP oligomers in the presence of each small molecule. In the absence of small 
molecule, hIAPP forms oligomers up to, and including, hexamers within 2 minutes of dilution 
into buffer (Figure 2c)10. In the presence of a 10-fold molar excess of a ‘negative’, non-
interacting small molecule such as ibuprofen (8), the same array of oligomers is observed 
(Figure 5a). When a ‘positive’ specific inhibitor (e.g. FG) (1) is added (Figure 5b), binding of 
the small molecule to the peptide monomer is observed, with no higher order hIAPP species 
detected. This lack of oligomers is likely due to inhibition of self-assembly achieved by small 
molecule binding to the monomeric peptide. When a non-specific binder (e.g. 1H-B-SA (5)) 
is added (Figure 5c), multiple copies of ligands ( seven molecules) bound to each 
monomeric conformer are observed in the mass spectrum, indicative of a non-specific 
interaction. Conversely, the spectrum of hIAPP in the presence of CR (4) (Figure 5d) shows 
a multitude of higher order species. However, the majority of these peaks correspond to 
multimers of CR resulting from self-association of the small molecule. Peptide monomers are 
also observed in the spectrum but not peptide oligomers, which may result from their low 
intensities compared with CR aggregates, or their absence. The ESI-IMS-MS data presented 
reveal clear differences between the spectral ‘fingerprint’ of hIAPP undergoing no 
interaction, specific, non-specific or colloidal interactions with small molecules. 
Consequently, ‘hits’ from screens of potential small molecule inhibitors can be distinguished 
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readily from negative, colloidal or non-specifically bound molecules using ESI-IMS-MS and, 
based on simple characterization of the spectral features, selected for further 
characterization or optimization.  
 
Screening mixtures of small molecules using ESI-IMS-MS  
To validate the use of ESI-IMS-MS as a potential high-throughput screen (HTS) for small 
molecule interactions with aggregating proteins/peptides, several small molecules were 
mixed and added to hIAPP in combination. The ability of ESI-IMS-MS to differentiate 
between molecules able to bind specifically to the target protein/peptide from their non-
binding or non-specific binding counterparts was then assessed. This approach has two key 
advantages: firstly, it decreases the time taken to screen an array of molecules (5-10 
molecules/min); secondly, in competition, the strongest binders as observed in the gas-
phase should out-compete negative, weak or colloidal inhibitors. This method is 
demonstrated using FG (positive) (1), CR (colloidal) (4), 1H-B-SA (non-specific) (5) and four 
small molecules that do not bind to hIAPP (negative) (7-10). When added to hIAPP (32 µM) 
in combination (160 µM each small molecule), FG and CR behave as each one behaved 
when added individually, i.e. FG binds specifically to the target peptide and CR self-
associates without any specific protein interaction being observed (Supplementary, Figure 
S9). The presence of equimolar CR does not prevent FG from binding to hIAPP, nor does 
the presence of equimolar FG inhibit the self-association of CR. We also tested the ability of 
FG to bind hIAPP in the presence of mixtures of small molecules that do not bind (aspirin 
(7), ibuprofen (8), benzimidazole (9) and hemin (10)). The results showed that of the five 
small molecules present, only FG binds hIAPP (Supplementary, Figure S9). Additionally, the 
presence of a high concentration of a non-specifically binding small molecule did not perturb 
the interaction of FG with hIAPP (Supplementary, Figure S10). In the unlikely event that two 
positive inhibitors are encountered in the same mixture, the molecule which binds most 
stably in the gas-phase will out-compete the other. This is the case when FG (1) and EGCG 
(2) are each added in a 5-fold molar excess to hIAPP (Supplementary, Figure S10). FG and 
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hIAPP have favourable electrostatic interactions25, whereas EGCG is thought to bind 
principally via hydrophobic interactions34. Given the known ability of electrostatic interactions 
to be preserved in the gas-phase over their hydrophobic counterparts, FG out-competes 
EGCG. The relative affinity of these two different ligands for hIAPP therefore cannot be 
deduced from these data. To control for the effects of the chemistry of binding determining 
the relative intensity of bound peaks observed by ESI-MS22,23, the Kd of small molecules 
identified as a “hit” in a mixture of compounds should be confirmed using other biophysical 
methods in solution. 
 
ESI-IMS-MS as a generic screen for amyloid inhibitors 
To demonstrate the applicability of ESI-IMS-MS as a generic tool for screening and 
classifying inhibitors of aggregating systems, we screened for inhibitors of $ȕ assembly1. 
The sequeQFHVRIK,$33)LJXUHDDQG$ȕ)LJXUHDVKDUHLGHQWLW\DQG
similarity, with the core VHTXHQFHV$ȕ–32) and hIAPP (21–27) believed to be involved 
in the self-assembly of each peptide35-37 being most similar. $ȕ (32 µM) was incubated 
alone or with tramiprosate (6), hemin (10) or EGCG (2) at 10:1 molar ratio of small molecule 
to $ȕ$ȕalone, when analyzed by ESI-MS, gives rise to dominant 3+ and 4+ monomer 
charge state ions (Figure 6b) and oligomeric species from dimer through pentamer (Figure 
6c) en route to long straight amyloid fibrils. 
 
Tramiprosate (6) has been shown to retard $ȕDQG$ȕILEULOODWLRQin vivo, likely via 
competition with glycosaminoglycan (GAG) binding to the peptide38,39. The mass spectrum of 
a 10:1 molar ratio of tramiprosate:$ȕpeptide (Figure 6d) indicates a non-specific 
interaction which may explain how tramiprosate interferes with GAG binding to Aȕin vivo38. 
ThT and TEM data reveal fibrillation in the absence and presence of tramiprosate (6) 
(Figures 6e,f), corroborating these findings. Hemin (10) (along with other porphyrins) has 
also been reported to LQWHUIHUHZLWK$ȕILEULOODWLRQ17,40. Here, hemin has no observed effect on 
AȕVHOI-DVVHPEO\DVMXGJHGE\LWVLQDELOLW\WRELQGWR$ȕ)LJXUHGDQGWKHUHVXOWDQW
11 
 
formation of fibrils (Figure 6f). Notably, no increase in ThT fluorescence is observed in the 
presence of hemin, presumably because the small molecule either interferes with ThT 
fluorescence or prevents ThT binding (Figure 6e). Conversely, EGCG (2), binds specifically 
WR$ȕPRQRPHUIRUPLQJD(*&*$ȕFRPSOH[)LJXUHGUHVXOWLQJLQWKHIRUPDWLRQ
of amorphous aggregates and the absence of long straight amyloid fibrils (Figures 6e,f). The 
results demonstrate, therefore, the utility of ESI-MS as a screen for inhibitors of different 
amyloid systems. 
 
Focused screen for the identification of novel inhibitors of amyloid formation 
To validate further the MS-based assays, we next performed a screen of a library of novel 
molecules with structural similarity to the aggregation inhibitors previously reported 
(Supplementary, Table S2). We reasoned that a focussed screen of this type would be a 
rigorous test for the ESI-IMS-MS assay and indicate the suitability of this approach for HTS. 
Focused screening is a well-versed method to improve the hit-rate of a HTS by seeding a 
screening library with compounds which have a higher probability to inhibit, or bind to, the 
target compared with random screening41. The screening method uses the structural 
information from known bioactive ligands to identify novel compounds with similar structure, 
and hence potential biological activity. For proof of principle, five known inhibitors of hIAPP 
and/or $ȕ0 aggregation (vanillin42, resveratrol43, curcumin44, chloronaphthoquinine-
tryptophan45 and EGCG10) were selected as queries to seed a focussed library of 
compounds for screening. The seeding process involved assessment of each of the 
inhibitors for structural similarity to an in-house, structurally diverse library of 50,000 lead-like 
small molecules using the programme Rapid Overlay of Chemical Structures (ROCS)46.  A 
subset of 20 compounds was then chosen for analysis using the comparator (ROCS 
Combiscore) with consideration to maximal structural diversity of the proposed screening 
set. The 20 compounds (molecules 11-30) selected were screened, together with 
compounds 31-40 which have been reported to inhibit other forms of fibrillogenesis by other 
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polypeptides (Supplementary, Table S2). LogP values of these compounds are shown in 
Supplementary, Figure S11. 
 
Of these 30 compounds screened, one was found to inhibit hIAPP aggregation (compound 
26), three demonstrated non-specific binding to hIAPP (compounds 13, 25 and 27) and the 
remainder did not bind (Supplementary, Table S2). The newly disovered inhibitor (compound 
26) is a non-obvious structural mimetic of chloronaphthoquinine–tryptophan (Supplementary, 
Figure S12). In the presence of a 10-fold molar excess of compound 26, hIAPP monomer 
shows evidence of specific ligand binding, fibril formation is inhibited and amorphous 
aggregates result (Supplementary, Figure S13).  
 
 
 
<Uncaptioned graphic structures 26 13 25 and 27> to be placed here 
 
 
 
Automation of ESI-MS allows identification of novel compounds from focussed libraries in 
the form of a semi-HTS. For proof of principle, we performed analyses from a 96-well plate 
format, with data acquisitions of one minute per well. The results demonstrate that spectra of 
high quality can be obtained in a reproducible manner (Supplementary, Figure S14). With 
this method, 96 novel potential inhibitors could be screened per plate, consuming ~1 mg 
peptide. Using robotic automation, ~1000 compounds can be screened in less than 24 
hours. By assaying mixtures of five compounds in parallel, 480 molecules could be screened 
per plate, increasing the screening rate to ~5000 novel compounds per day. 
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Conclusions 
The data presented demonstrate the use of ESI-IMS-MS as a HTS for inhibitors of amyloid 
assembly. This approach allows rapid identification of protein-ligand interactions, using 
microliter sample volumes and milligrams of protein, and provides information-rich data 
concerning the identity of the interacting species (monomer or oligomer), the nature of 
binding (specific, non-specific or colloidal) and the effect of the ligand on protein aggregation 
(monomer binding, shift in monomer conformational equilibrium, disassembly of oligomers). 
The use of IMS in conjunction with ESI-MS serves further to allow a reliable and easily 
interpretable screen based purely on the appearance of 3D Driftscope plots, without 
requiring complex data analysis. The results establish this method as a powerful tool with 
unique analytical capability for the discovery of small molecule leads in the drug discovery 
field. Additionally, a novel inhibitor of hIAPP aggregation has been identified based on 
analysis of a library of small molecules, illustrating the potential of this method as a HTS. 
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Methods  
Sample preparation for MS  
hIAPP was synthesized using Fmoc chemistry, oxidised using dimethyl sulfoxide (DMSO) to 
form the disulfide bond linking residues Cys 2 – Cys 7, and purified via HPLC. Hydrochloric 
acid was used as the counter ion in all HPLC buffers as trifluoroacetic acid can affect the 
kinetics of amyloid formation47 (see Supplementary, Section 2 for further details). $ȕZDV
expressed recombinantly in E. coli (Supplementary, Section 2). Lyophilized hIAPP samples 
were dissolved in DMSO at a final peptide concentration of 3.2 mM. After 24 h incubation at 
25 °C, stock solutions were diluted 100 -fold into 200 mM ammonium acetate, pH 6.8, to a 
ILQDOSHSWLGHFRQFHQWUDWLRQRIȝ0IRU06DQDO\Vis. The final concentration of DMSO was 
1 % (v/v/\RSKLOL]HG$ȕZDVGLVVROYHGDW0LQP0DPPRQLXPDFHWDWHS+
1 % DMSO (v/v), and centrifuged at 13,000 g, 4 °C for 10 min prior to analysis. All samples 
were incubated at 25 °C in 96 -well plates without agitation.  
 
ESI-(IMS)-MS analysis  
A Synapt HDMS quadrupole-time-of-flight mass spectrometer (Micromass UK Ltd., Waters 
Corpn., Manchester, UK), equipped with a Triversa NanoMate (Advion Biosciences, Ithaca, 
NY, USA) automated nano-ESI (nESI) interface, was used for these analyses. The 
instrument has a traveling-wave IMS device situated in between the quadrupole and the 
time-of-flight analyzers, and has been described in detail elsewhere48K,$33RU$ȕ
samples were analyzed using positive ionization nESI with a capillary voltage of 1.7 kV and 
a nitrogen nebulizing gas pressure of 0.8 psi. The following instrumental parameters were 
used: cone voltage 30 V; source temperature 60 °C; backing pressure 1.6 mBar; ramped 
traveling wave height 7–20 V; traveling wave speed 300 m/s; IMS nitrogen gas flow 20 
mL/min; IMS cell pressure 0.55 mBar. Data were processed by use of MassLynx v4.1 and 
Driftscope software supplied with the mass spectrometer. The m/z scale was calibrated with 
aq. CsI cluster ions.  
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Collision induced dissociation (CID) tandem mass spectrometry (MS/MS) was carried out in 
the trap collision cell of the mass spectrometer, using argon gas. The quadrupole analyzer 
was used to select ions representing ligand-bound monomer complexes and increasing 
collision energy was applied to the trap collision cell in 10 V increments from 10-100 V, until 
the ligands were completely dissociated from the monomer ions. Automation of the 
NanoMate for high throughput experiments was programmed enabling samples in each of 
the 96-wells to be analyzed for one minute, consecutively. 
 
For analysis of ligand binding to monomeric peptide, K,$33RU$ȕȝ0Zas dissolved 
LQP0DPPRQLXPDFHWDWHS+FRQWDLQLQJȝ0RUȝ0RIVPDOOPROHFXOH)RU
analysis of these samples by nESI-MS, a cone voltage of 30 V was used to preserve protein-
ligand interactions, and a backing pressure of 1.6 mbar was applied. Data were acquired 
over the range m/z 200–6,000.  
 
Thioflavin-T (ThT) fluorescence assays  
Samples were added to a 96-well plate (Corning Costar 3915, Corning Life Sciences, 
Amsterdam, The Netherlands), sealed with clear sealing film and incubated in a FLUOstar 
OPTIMA plate reader (BMG Labtech, Aylesbury, Bucks, UK) for 5 days at 25 °C without 
DJLWDWLRQ(DFKȝ/VDPSOHFRQWDLQHG7K7ȝ0DQGSHSWLGHȝ0LQP0
ammonium acetate, pH 6.8 and a 1 % (v/v) final concentration of DMSO. The thioflavin-T 
studies used excitation and emission filters of 430 and 485 nm, respectively. 
 
Transmission electron microscopy (TEM)  
7KH7(0LPDJHVRIHDFKȝ0SHSWLGHVROXWLRQZHUHDFTXLUHGDIWHUGD\VLQFXEDWLRQDW
25 °C using a JEM-1400 (JEOL Ltd., Tokyo, Japan) transmission electron microscope. 
Carbon grids were prepared by irradiation under UV light for 30 min and stained with 4 % 
(w/v) uranyl acetate solution as described previously49.  
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Virtual screening 
The structure of each of the five query molecules (vanillin, resveratrol, curcumin, 
chloronaphthoquinine-tryptophan and epigallocatechin-3-gallate (EGCG)) was minimized to 
the lowest energy conformer using LigPrep50.  The minimized conformers were used as the 
query scaffold for virtual screening of an in-house library of 50,000 structurally diverse, novel 
small molecules using Rapid Overlay of Chemical Structures (ROCS)46. ROCS is a 3D 
method that matches the shape of a molecule to the shape of the query molecule. It also 
incorporates pharmacophoric features in assessing overlays such that the ROCS 
Combiscore measures the similarity of the matched shapes as well as the matched 
pharmacophoric features. Virtual hits were pooled and ranked according to the ROCS 
Combiscore parameter and 20 of the top 100 compounds were selected for screening based 
on a qualitative assessment of structural diversity. In addition, a further ten compunds 
chosen from the literature as known inhibitors of amyloid formation by different polypeptide 
sequences were included in the screen. 
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Figure Legends 
Figure 1. Schematic diagram of the basis of the ESI-IMS-MS screen and a selection of the 
small molecules utilized for screen validation. (a-d) Schematic of expected ESI mass spectra 
resulting from different interactions between peptide/protein monomer (denoted m) and 
potential inhibitors (denoted L). Oligomers are denoted o; charge states are in superscript. 
(a) A specific ligand (termed positive) will result in a binomial distribution of bound peaks 
(pink)21; (b) the presence of a colloidal inhibitor will lead to spectra containing overlapping 
peaks resulting from the heterogeneous self-association of the small molecule (orange 
peaks); (c) a non-specific ligand will bind and result in a Poisson distribution of bound peaks 
(green)21; (d) the presence of a non-interacting small molecule (termed negative) will result 
in spectra similar to those of peptide alone; (e) list of ten small molecules analyzed initially 
for inhibition of hIAPP aggregation during ESI-MS screen validation. Colors correspond to 
binding-mode classification by mass spectra (a-d): specific = pink, colloidal = orange, non-
specific = green, negative = gray. 
 
Figure 2. hIAPP forms an array of oligomeric species en route to long-straight amyloid 
fibrils. (a) Primary sequence of hIAPP. The peptide has a disulfide bridge between Cys-2 
and Cys-7 and an amidated C-terminus; (b) ESI-MS mass spectrum of hIAPP. Numbers 
above peaks denote oligomer order, with the positive charge state of ions in superscript; (c) 
ESI-IMS-MS Driftscope plot of the hIAPP monomer (1) through hexamer (6), present 2 min 
after diluting the monomer to a final peptide concentration of 32 µM in 200 mM ammonium 
acetate, pH 6.8. ESI-IMS-MS Driftscope plots show IMS drift time versus mass/charge (m/z) 
versus intensity (z = square root scale). Inset: negative stain TEM image of hIAPP fibrils 
after 5 days in 200 mM ammonium acetate pH 6.8 buffer (25 °C, quiescent) (scale bar = 100 
nm). 
 
Figure 3. Inhibition of hIAPP amyloid assembly by Fast Green FCF (FG). (a) ThT 
fluorescence intensity over time of hIAPP alone (black circles) (32 µM peptide, 200 mM 
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ammonium acetate buffer, pH 6.8, 25 °C, quiescent) and with increasing FG:hIAPP m olar 
ratios: 1:1 (orange) and 10:1 (green), showing dose dependent decrease in formation of 
ThT-positive hIAPP species upon addition of FG. (b) Negative stain TEM images of hIAPP 
incubated with (i) 1:1 or (ii) 10:1 molar ratios of FG:hIAPP for 5 days (25 °C, qui escent) 
(scale bar = 100 nm), showing lack of fibrillation (ii) and formation of small/amorphous 
aggregates (i) of hIAPP in the presence of  FG. (c) Positive ion ESI mass spectra showing 
FG alone (i), or added at 32 µM (ii), or 320 µM (iii), to hIAPP (32 µM). FG binds to the 2+ 
and 3+ charge state ions of hIAPP monomer (bound peaks denoted with orange or green 
circles; number of circles represents number of ligands bound), and to the 4+ charge state of 
the hIAPP dimer (bound peak denoted with white circle). This binding mode is classified as 
specific. 
 
Figure 4. Colloidal inhibition and non-specific binding observed using ESI-IMS-MS. (a) ThT 
fluorescence intensity of hIAPP (black) (32 µM peptide, 200 mM ammonium acetate buffer, 
pH 6.8, 25 °C, quiescent) with Congo red (CR):hIAPP molar ratios: 1:1 (orange) and 10: 1 
(red) and with 1H-benzimidazole-2-sulfonic acid (1H-B-SA):hIAPP molar ratio: 10:1 (blue)). 
Inhibition of the formation of ThT-positive species is observed only in the presence of excess 
CR. (b) Negative stain TEM images of hIAPP incubated with 1:1 (i) or 10:1 (ii) molar ratios of 
CR or a 10:1 molar ratio of 1H-B-SA (iii) (5 days, 25 °C, quiescent) (scale  bar = 100 nm). 
Fibrils are observed in the presence of equimolar CR and excess 1H-B-SA but not in the 
presence of excess CR. (c) Positive ion ESI mass spectra showing CR added at 32 µM (i) or 
320 µM (ii), or 1H-B-SA added at 320 µM (iii), to hIAPP (32 µM). CR is not observed to bind 
to hIAPP when added at 32 µM (i) or 320 µM (ii), however CR self-aggregates at 320 µM (ii) 
(denoted nx+, where n is the number of CR molecules and x is the charge state of those ions 
(red peaks). This binding mode is classified as colloidal. Multiple copies of 1H-B-SA bind to 
the 2+ and 3+ hIAPP monomer ions (bound peaks denoted with blue circles, number of 
circles represents number of ligands bound), and to the hIAPP dimer (bound peaks denoted 
with white circles). This binding mode is classified as non-specific. 
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 Figure 5. ESI-IMS-MS demonstrates the mode of inhibition (specific/colloidal/non-specific) 
or lack of inhibition of hIAPP amyloid formation by small molecules. ESI-IMS-MS Driftscope 
plots of hIAPP and (a) ibuprofen; (b) FG (bound peaks denoted with yellow (13+ bound) or 
green (12+ bound)  circles, number of circles represents number of ligands bound); (c) 1H-B-
SA (bound peaks denoted with blue circles; and (d) CR (colloidal aggregates are denoted 
nx+, where n is the number of CR molecules and x is the charge state of the aggregate) (320 
µM small molecule) to hIAPP (32 µM). An example of a negative (a), a positive (b), a non-
specific (c) and a colloidal inhibitor (d) are illustrated. The numbers on the Driftscope plots 
indicate the oligomer order and the adjacent superscripted numbers show the charge state 
of those ions. 
 
Figure 6. $ȕDORQHDQGZLWKQRQ-specific, negative and specific binding small molecules. 
D3ULPDU\VHTXHQFHRIUHFRPELQDQWO\H[SUHVVHG$ȕZLWKDQDGGLWLRQDON-terminal 
PHWKLRQLQHE(6,PDVVVSHFWUXPRI$ȕ1XPEHUVDGMDFHQWWRSHDNVGHQRWHROLJRPHU
order, with the positive charge state of the ions in superscript; (c) ESI-IMS-MS Driftscope 
SORWRI$ȕDORQH0LQP0DPPRQLXPDFHWDWHS+ showing IMS drift time 
versus m/z versus intensity (z = square root scale); (d) positive ion ESI mass spectra 
VKRZLQJ0WUDPLSURVDWHLKHPLQLLRU(*&*LLLDGGHGWR$ȕSHSWLGH0
7UDPLSURVDWHELQGVPXOWLSOHFRSLHVWRWKHDQGLRQVRI$ȕPRQRPHU(bound peaks 
denoted with pink circles, number of circles represents number of ligands bound).This 
binding mode is classified as non-specific. Hemin (ii) does not bind and is classified as 
negative; (*&*LLLELQGVWRERWKWKHDQGLRQVRI$ȕPRQRPer (bound peaks are 
denoted with blue circles) and is classified as specific. (e) ThT fluorescence intensity of 
$ȕDORQHEODFNFLUFOHV in the presence of tramiprosate (pink circles), EGCG (blue circles) 
or KHPLQRUDQJHFLUFOHVDWVPDOOPROHFXOH$ȕmolar ratios of 10:1. Inhibition of the 
formation of ThT-positive species is observed in the presence of excess EGCG and 
interference with ThT fluorescence is observed in the presence of excess hemin. (f) 
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1HJDWLYHVWDLQ7(0LPDJHVRI$ȕDORQHLRULQFXbated with 10:1 molar ratios of 
tramiprosate (ii), hemin (iii) or  EGCG (iv) (5 days, 25 °C, quiescent); scale bar = 100 nm.  
)LEULOVDUHREVHUYHGE\$ȕDORQHDQGLQWKHSUHVHQFHRIH[FHVVtramiprosate and  hemin 
but not in the presence of excess EGCG. 
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